Know Cancer

or
forgot password

FEASIBILITY OF IMPLEMENTING PRE-TRANSPLANT PALLIATIVE CARE SUPPORT FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES


N/A
18 Years
N/A
Open (Enrolling)
Both
Hematopoietic/Lymphoid Cancer

Thank you

Trial Information

FEASIBILITY OF IMPLEMENTING PRE-TRANSPLANT PALLIATIVE CARE SUPPORT FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES


PRIMARY OBJECTIVES:

I. Pilot a palliative care intervention that begins prior to transplantation and continues
through the acute peritransplant period.

II. Determine the proportion of patients who enroll and the level of comfort / distress of
hematopoietic cell transplant (HCT) patients who meet with the palliative care team.

III. Pilot data collection mechanisms and cost retrieval in preparation for a randomized
clinical trial.

OUTLINE:

Patients undergo palliative care consultation before transplantation and at least once
monthly while they remain at the transplant center.


Inclusion Criteria:



- Written informed consent

- English as primary language

- Planned autologous or allogeneic hematopoietic cell transplantation

- Presence of co-morbidities (hematopoietic cell transplant co-morbidity index [HCT-CI]
score 3 or greater), high risk disease (relapse risk > 25%), or a planned type of
transplant (human leukocyte antigen [HLA]-mismatched allogeneic or myeloablative)
that places the patient at a higher than average risk of non-relapse mortality or
relapse

Exclusion Criteria:

- Major psychiatric diagnosis that impairs cognitive functioning or is not controlled
at the time of the approach, as judged by the patient's medical team

- First transplant of a planned tandem procedure (the second transplant is eligible)

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Outcome Measure:

Study participation rates defined as the proportion of patients who consent to enroll

Outcome Description:

Will mainly be descriptive.

Outcome Time Frame:

Up to 5 months

Safety Issue:

No

Principal Investigator

Stephanie Lee

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Authority:

United States: Federal Government

Study ID:

2659.00

NCT ID:

NCT01758484

Start Date:

April 2013

Completion Date:

Related Keywords:

  • Hematopoietic/Lymphoid Cancer
  • Hematopoietic cell transplantation
  • palliative care
  • Hematologic Neoplasms

Name

Location

Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington  98109